Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trilobatin is a natural dihydrochalcone glucoside, chemically described as phloretin with a β-D-glucopyranosyl at the 4' position; it occurs in the leaves of Lithocarpus polystachyus (Chinese “sweet tea”) and functions as a sweetening plant metabolite with reported antioxidant and anti‑inflammatory activities[1][8]. Preclinical studies report biological effects including improvement of DSS-induced colitis via suppression of NF‑κB signaling and modulation of gut microbiota in mice[3], regulation of glucose metabolism and insulin resistance through PI3K/Akt/GSK‑3β and Nrf2/Keap‑1 pathways in cell and STZ-mouse models[4], neuroprotection and cognitive benefit in Alzheimer’s disease models via direct binding to HMGB1 and activation of SIRT3/SOD2 signaling[6], and antidepressant-like effects in CUMS mice with identification as a naturally occurring GPR158 ligand[9][7]. It is available as a research chemical; there is no evidence of clinical approval as a pharmaceutical drug[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trilobatin.